Trial Profile
Modulating proinflammatory processes using tocilizumab in major depressive disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2019
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Major depressive disorder
- Focus Biomarker; Pharmacodynamics
- 21 Jun 2018 New trial record